Education
About Us
Working with TipRanks
Follow Us
Verrica Pharmaceuticals (VRCA)
NASDAQ:VRCA
VRCA Stock Chart & Stats
$3.53
-$0.03(-3.87%)
At close: 4:00 PM EST
$3.53
-$0.03(-3.87%)
Day’s Range― - ―
52-Week Range$3.43 - $15.55
Previous CloseN/A
Volume115.12K
Average Volume (3M)544.61K
Market Cap
$33.34M
Enterprise Value$73.81M
Total Cash (Recent Filing)$15.40M
Total Debt (Recent Filing)$38.89M
Price to Earnings (P/E)―
Beta0.92
Next Earnings
Nov 10, 2025EPS Estimate
-0.51Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.02
Shares Outstanding9,445,768
10 Day Avg. Volume417,535
30 Day Avg. Volume544,605
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap2.21
Enterprise Value/Revenue5.02
Enterprise Value/Gross Profit5.73
Enterprise Value/Ebitda-1.88
Forecast
1Y Price Target
$20.00Price Target Upside466.57% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Bulls Say, Bears Say
Bulls Say
Funding And Financial StabilityNon-dilutive financing was secured, providing operational funding through 2025 and into 2026.
Market AdoptionManagement is executing on the new strategy, with step-wise expansion and focus in key territories with high molluscum prevalence and strong insurance coverage.
Sales PerformanceYcanth sales increased by 33%, slightly surpassing market expectations.
Bears Say
Going Concern IssueA 'going concern' remains despite the recent financing achievements.
Profitability ConcernsThe company is currently not profitable, making a long-term financial solution necessary.
Verrica Pharmaceuticals News
VRCA FAQ
What was Verrica Pharmaceuticals’s price range in the past 12 months?
Verrica Pharmaceuticals lowest stock price was $3.43 and its highest was $15.55 in the past 12 months.
What is Verrica Pharmaceuticals’s market cap?
Verrica Pharmaceuticals’s market cap is $33.34M.
When is Verrica Pharmaceuticals’s upcoming earnings report date?
Verrica Pharmaceuticals’s upcoming earnings report date is Nov 10, 2025 which is in 9 days.
How were Verrica Pharmaceuticals’s earnings last quarter?
Verrica Pharmaceuticals released its earnings results on Aug 12, 2025. The company reported $0.02 earnings per share for the quarter, beating the consensus estimate of -$0.9 by $0.92.
Is Verrica Pharmaceuticals overvalued?
According to Wall Street analysts Verrica Pharmaceuticals’s price is currently Undervalued.
Does Verrica Pharmaceuticals pay dividends?
Verrica Pharmaceuticals does not currently pay dividends.
What is Verrica Pharmaceuticals’s EPS estimate?
Verrica Pharmaceuticals’s EPS estimate is -0.51.
How many shares outstanding does Verrica Pharmaceuticals have?
Verrica Pharmaceuticals has 9,445,768 shares outstanding.
What happened to Verrica Pharmaceuticals’s price movement after its last earnings report?
Verrica Pharmaceuticals reported an EPS of $0.02 in its last earnings report, beating expectations of -$0.9. Following the earnings report the stock price went down -3.372%.
Which hedge fund is a major shareholder of Verrica Pharmaceuticals?
Currently, no hedge funds are holding shares in VRCA
Verrica Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$20.00 (466.57% Upside)
$20.00 (466.57% Upside)
Blogger Sentiment
Bullish
VRCA Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 325.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.6%
Last 30 Days ▲ 5.7%
Last 30 Days ▲ 5.7%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-77.93%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-24.81%
Trailing 12-Months
Company Description
Verrica Pharmaceuticals
Verrica Pharmaceuticals Inc., a dermatology therapeutics company, develops and commercializes treatments for people with skin diseases in the United States. The company's lead product candidate includes VP-102 for the treatment of molluscum contagiosum; that has completed Phase II clinical trial for the treatment of external genital warts; and which is in Phase II clinical trial for treating common warts. It is also developing cantharidin-based product candidate, VP-103 for treating plantar warts. The company has a license and collaboration agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize LTX-315 for dermatological oncology indications. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.
VRCA Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant growth in YCANTH sales, strategic partnerships, and improved financial performance, although concerns about future cash flow and reduced R&D expenses were noted.View all VRCA earnings summariesVRCA Stock 12 Month Forecast
Average Price Target
$20.00
▲(466.57% Upside)
Technical Analysis
Generation Bio
―
Aziyo Biologics
―
Evaxion Biotech
―
LAVA Therapeutics
―
Liminatus Pharma
―
Ownership Overview
44.85% Insiders
3.24% Mutual Funds
0.81% Other Institutional Investors
48.83% Public Companies and
Individual Investors